MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bioAffinity Technologies, Inc. - Warrant (NQ:BIAFW)

0.0875 -0.0125 (-12.50%)
Streaming Delayed Price Updated: 2:33 PM EDT, Jul 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 110
Open 0.0875
Bid (Size) 0.0750 (1,200)
Ask (Size) 0.1000 (1,000)
Prev. Close 0.1000
Today's Range 0.0875 - 0.0875
52wk Range 0.0525 - 0.8121
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
From bioAffinity Technologies, Inc.
Via Business Wire

Performance

YTD
-65.9%
-65.9%
1 Month
-37.3%
-37.3%
3 Month
-72.1%
-72.1%
6 Month
-71.8%
-71.8%
1 Year
-45.3%
-45.3%

More News

Read More
News headline image
bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Closing of $3.2 Million Offering
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Pricing of $3.2 Million Offering
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for U.S. Veterans
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
From bioAffinity Technologies, Inc.
Via Business Wire

Frequently Asked Questions

Is bioAffinity Technologies, Inc. - Warrant publicly traded?
Yes, bioAffinity Technologies, Inc. - Warrant is publicly traded.
What exchange does bioAffinity Technologies, Inc. - Warrant trade on?
bioAffinity Technologies, Inc. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for bioAffinity Technologies, Inc. - Warrant?
The ticker symbol for bioAffinity Technologies, Inc. - Warrant is BIAFW on the Nasdaq Stock Market
What is the current price of bioAffinity Technologies, Inc. - Warrant?
The current price of bioAffinity Technologies, Inc. - Warrant is 0.0875
When was bioAffinity Technologies, Inc. - Warrant last traded?
The last trade of bioAffinity Technologies, Inc. - Warrant was at 07/23/26 02:33 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story